Phillip A. Sharp, Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 45,979 shares at $152.40 ($7.0M) on 2024-02-29, disclosed to the SEC on 2024-03-01.
Scheduled sale ($7.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $150.60 | 13,005 | $2.0M | 28.1% |
| 2 | $151.43 | 13,557 | $2.1M | 29.5% |
| 3 | $151.43 | 13,557 | $2.1M | 29.5% |
| 4 | $152.40 | 915 | $139K | 2.0% |
| 5 | $153.62 | 1,906 | $293K | 4.2% |
| 6 | $153.62 | 1,906 |
| $293K |
| 4.2% |
| 7 | $154.07 | 101 | $16K | 0.2% |
| 8 | $156.54 | 516 | $81K | 1.2% |
| 9 | $156.54 | 516 | $81K | 1.2% |
| Total | $151.52 avg | 45,979 | $7.0M | 100% |
| Filing → |
| ALNY | SELL | 2022-02-11 | $4.5M | — | Filing → |
| ALNY | SELL | 2020-11-30 | $7.5M | — | Filing → |
| ALNY | SELL | 2020-02-13 | $3.9M | — | Filing → |